NASDAQ:ACRX
Delisted
AcelRx Pharmaceuticals Stock News
$0.86
+0 (+0%)
At Close: Apr 08, 2024
HAYWARD, Calif., June 1, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
09:39am, Monday, 31'st May 2021
AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
HAYWARD, Calif., May 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative
AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward
04:10am, Friday, 21'st May 2021
AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward
Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5
11:44am, Tuesday, 18'th May 2021
Biotech penny stocks continue to heat up; here's 4 under $5 to look into The post Biotech Penny Stocks Are On Fire Today, Here's 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2021 Results - Earnings Call Transcript
09:56pm, Monday, 17'th May 2021
AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vince Angotti on Q1 2021 Results - Earnings Call Transcript
AcelRx Pharmaceuticals: Q1 Earnings Insights
04:40pm, Monday, 17'th May 2021
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year over year to ($0.08), whi
AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group
10:18am, Thursday, 13'th May 2021
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the results of a study on the intraope
HAYWARD, Calif., May 13, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovativ
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
03:47pm, Monday, 03'rd May 2021
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure
10:40am, Thursday, 08'th Apr 2021
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual tablet) for same-day surgical procedures in
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in Patients Taking Buprenorphine Who Require a Surgical Procedure
08:30am, Thursday, 08'th Apr 2021
REDWOOD CITY, Calif., April 8, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innov
AcelRx Pharmaceuticals Announces Appointment of Marina Bozilenko to the Board of Directors
08:30am, Wednesday, 31'st Mar 2021
REDWOOD CITY, Calif., March 31, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative th
REDWOOD CITY, Calif., March 25, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative the
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. (ACRX)
09:53pm, Sunday, 21'st Mar 2021
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX). Such in
